BIO-Europe C-Suite Survey: Biopharma dealmaking set to accelerate, but investor caution still caps ambition
- 75% of biopharma leaders expect partnering and M&A appetite to increase over the next 12 months, none expect a decline
- 69% expect access to capital to improve, yet 79% identify investor risk aversion as the biggest constraint on biotech investment
- 52% say US policy uncertainty has made Europe more attractive to build and partner in, though the US and China still lead as expected sources of partnerships
London, UK – 7 October 2026 – BIO-Europe, the must-attend global biopharma strategy forum, today publishes its inaugural Biopharma C-Suite Agenda Survey 2026, providing a timely, data-led view of how senior industry leaders are navigating a period of renewed dealmaking appetite, persistent capital pressure and shifting global competition. The survey of 81 senior biopharma executives, including 50 CEOs, captures an industry balancing greater confidence with continued constraint.
